Xenon Pharmaceuticals raises $707.7M in public offering of common shares and pre-funded warrants

Xenon Pharmaceuticals Inc.

Offered 12.2M common shares at $57.00 plus pre-funded warrants for 877,194 shares at $56.9999 each.
Underwriters exercised option to purchase an additional 1.7M common shares in full.
Net proceeds of approximately $707.7 million after underwriting discounts and estimated expenses.
Offering closed on March 12, 2026; warrants have $0.0001 exercise price and are immediately exercisable.
Lead underwriters include J.P. Morgan, Jefferies, TD Securities, Stifel, RBC Capital Markets, and William Blair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.